HEMODIALYSIS AND HEMOPERFUSION IN THE TREATMENT OF DRUG OVERDOSES
The vast majority of drug overdoses can be managed by routine supportive measures. The excretion of drugs that are eliminated from the body by the kidney can be augmented by increasing the urine flow rate and expanding the extracellular fluid volume. Alteration of the pH of the urine may increase the renal excretion of some organic anions and cations . The use of extracorporeal methods to remove drugs is a valuable and potentially life-saving procedure in some patients with drug overdoses.
Principles of Hemodialysis/Hemoperfusion. Hemodialysis is most effective for the removal of small molecular weight species that are water-soluble and not highly protein-bound. Hemodialysis may also be useful in the correction of severe metabolic acidosis induced by an overdose of aspirin or by intoxication with methanol or ethylene glycol . Hemoperfusion removes solutes by a process of adsorption onto an activated charcoal column or other resin adsorbents (e.g., Amberlite). Hemoperfusion is most useful for removing lipid-soluble or highly protein-bound species .
Complications and Indications. Use of these ancillary means of removal of drugs and toxins is not without risk, particularly in the patient who is unstable. Both hemodialysis and hemoperfusion require systemic heparinization and insertion of vascular catheters. Vascular instability may be a problem during hemoperfusion, as the extracorporeal volume of blood is about 500 ml. Adherence of platelets to the resin column in hemoperfusion may result in significant thrombocytopenia.
The use of these modalities in the management of drug intoxications should be undertaken only when there are clear indications. The general indications are outlined below. A patient with a drug overdose and with any of the following features should be considered for treatment with hemodialysis or hemoperfusion:
1.A severe intoxication associated with hypotension, hypoventilation, or hypothermia and poorly responsive to usual supportive measures.
2.The presence of prolonged coma, particularly in patients with underlying pulmonary disease.
3.The presence of significant hepatic or renal disease that might interfere with drug metabolism or elimination.
4.The presence of a drug or substance that is either directly toxic to tissues or is metabolized to a direct tissue toxin (e.g., methanol, ethylene glycol).
5.The presence of a potentially fatal blood level of a drug or a toxin.
- EMBOLIC DISEASE
- CIRCULATORY PHYSIOLOGY
- Visualization of the Biliary Tree
- ACUTE AND CHRONIC HEPATITIS - DEFIRILTIORI
- Differential Diagnosis and Evaluation of the Patient
- INFECTIVE ENDOCARDITIS
- Potassium Homeostasis
- DIAGNOSTIC APPROACH TO HEPATIC NEOPLASMS
- NORMAL ABSORPTION
- VENTILATION
- DC CARDIOVERSION AND DEFIBRILLATION
- Systemic Vasculitides
- Aminoaciduria
- Factors Involved in the Choice of Type of Dialysis
- Upper GI Bleeding
- GENERAL MANAGEMENT OF MYOCARDIAL INFARCTION
- CLINICAL APPROACH TO LIVER DISEASE
- SMOKING CESSATION
- Minimal Change Nephropathy
- NONPENETRATING TRAUMA
- Women’s Health Program
- PROSTHETIC VALVES
- PRE-EXCITATIOIi SYNDROMES
- DRUG-ASSOCIATED RENAL INJURY
- GLOMERULAR DISEASE
- Metabolism of Drugs in Patients with Renal Insufficiency
- Procainamide
- ACUTE PANCREATITIS
- EFFECTS OF PULMONARY HYPERTENSION ON PULMONARY FUNCTION
- RISK FACTORS
- PHYSICAL EXAMINATION
- History and Physical Examination
- Verapamil
- Clinical Assessment of Anemia
- CLINICAL MANIFESTATIONS